Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region

Dubischar, Katrin; Kadlecek, Vera; Sablan, Benjamin; Borja-Tabora, Charissa; Gatchalian, Salvacion; Eder-Lingelbach, Susanne; Kiermayr, Sigrid; Spruth, Martin; Westritschnig, Kerstin

doi:10.1097/inf.0000000000001615

Cited by 19 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neutralizing antibody titer prevalence is proposed to be related to the persistence of antibodies (Dubischar et al, 2017;Vadrevu et al, 2019). The current study was conducted in a JE endemic country where natural exposure to JEV may have affected the outcomes and confirmed high NAb persistence in 1605 participants aged >15 years in South Korea.…”

Section: Age Yearssupporting

confidence: 65%

Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea

Lee

Choi

Park

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Background: The incidence of Japanese encephalitis (JE) markedly decreased after the national immunization program in Korea, but is still intermittently reported in adults. Prospective studies are needed to determine whether JE virus (JEV)-neutralizing antibody (NAb) levels decline with age after the final JE vaccination. This study evaluated the titers of NAbs against JEV in Korean adolescents and adults. Methods: Specimens were collected from normal, healthy individuals aged 1 to !70 years (a total of 1605 cases) from five regional hospitals in Korea. Neutralizing antibody (NAb) titers were determined using a pseudotyped JEV NAb assay. Results: The JEV NAb-positive population was >95% in the 15-29 years age group, 89.42% in the 30-44 years age group, 75.24% in the 55-59 years age group, and 59.77% in the !70 years age group. NAb titers from the 20 to 70 years age groups showed a progressive decrease in proportion to age (p < 0.0001). Conclusions: Retention of NAbs after the final JE vaccination in childhood is a key indicator of the vaccination program and will have a significant impact on future JE prevention strategies.

show abstract

Section: Age Yearssupporting

confidence: 65%

Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea

Lee

Choi

Park

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In endemic countries, higher prevaccination dengue titers are known to result in lower JE postvaccination titers [ 22 ]. We hypothesize that the relatively lower postvaccination JE titers in the current study may be attributable to a heightened exposure to dengue, albeit it is well known that flavivirus antibodies cross-react with other flaviviruses [ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…In JE-endemic areas, due to constant natural exposure to flaviviruses, the duration of protective responses (from a JE vaccine) is expected to be longer than that in nonendemic areas. In endemic countries, higher JE seroprevalence has been associated with persistence of antibodies towards JE [ 22 ]. An equal number of children in both groups (approximately 52%) and across all sites experienced natural boosting (based on higher immunogenicity titers on day 720 when compared with day 360), a proportion high enough to contribute to maintenance of responses ( Figure 2 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Vadrevu

Sriram

Khalatkar³

et al. 2019

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Background This study reports immunogenicity, safety, and interchangeability of a single-dose, inactivated, Vero-cell derived, JENVAC to the live-attenuated SA 14-14-2 vaccine in healthy children. Methods This phase 4, multicenter, open-label, randomized, control trial enrolled 360 children who were equally randomized to receive a single dose of either JENVAC or SA 14-14-2. Children were followed at various time points, until 2 years (day 720) postvaccination, upon which a subset from each group was divided and allocated to a receive a booster dose or the other vaccine. Results At all time points, immunological measures were statistically higher in the JENVAC group. In the interchangeability study, children receiving 2 doses of JENVAC reported significantly higher response compared with 2 doses of SA 14-14-2. No difference in adverse events was observed. These corroborate with excellent seroprotection after the first dose of an earlier JENVAC study. Conclusions A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year. We report appreciable interchangeability between both vaccines, with JENVAC/JENVAC combination exhibiting the highest immune response. JENVAC is now licensed as a single-dose Japanese encephalitis vaccine.

show abstract

“…Zudem scheinen der Klimawandel und Faktoren, welche mit zunehmenden landwirtschaftlichen Aktivitäten in Verbindung stehen, die geografische Ausbreitung der Erkrankung zu begünstigen, sodass zuletzt eine Ausweitung der JBE-Impfindikation gefordert wurde (23). Der in Deutschland zugelassene inaktivierte Totimpfstoff mit JBE-Virus Stamm SA-14-2 (Ixiaro ® ) wird in Verozellen hergestellt, an Aluminiumhydroxid adsorbiert und ist im Gegensatz zu der alten in Mäusehirnen hergestellten Nakayama-Vakzine sehr gut ver-träglich (24)(25)(26). Die Grundimmunisierung erfolgt zweimal im Abstand von 28 Tagen bis zum vollendeten 3.…”

Section: Ab 2 Monaten Japanische Enzephalitisunclassified

Reiseimpfungen bei Kindern und Jugendlichen

Rau¹,

Kobbe²

2018

Kinder- und Jugendmedizin

View full text Add to dashboard Cite

ZusammenfassungImpfungen sind ein wichtiger Teil der medizinischen Beratung vor Auslandsreisen mit Kindern und Jugendlichen. Viele impfpräventable Krankheiten stellen für diese Altersgruppen ein besonderes Risiko dar. Für die meisten verfügbaren Impfstoffe gelten bestimmte Mindestaltersgrenzen. Bei der Beratung sollte zunächst der aktuelle Impfstatus gemäß STIKO-Empfehlungen überprüft werden. Die Reiseimpfempfehlung richtet sich vor allem nach Reiseziel, Reisedauer und Reisestandard. Daneben sind Einreisebestimmungen des Ziellandes und aktuelle Ausbrüche zu beachten. Bei besonderen Reiseanlässen wie Besuchen von Freunden und Verwandten, Großveranstaltungen, Langzeitaufenthalten, Backpacking oder Freiwilligendiensten ist die Indikation zur Immunisierung großzügiger zu stellen. Die Impfserie sollte idealerweise zwei Wochen vor Ausreise abgeschlossen sein. Auch kurzfristigere Impfungen können noch sinnvoll sein.

show abstract

Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region

Abstract: IXIARO is highly immunogenic at both doses tested in the pediatric population, leading to protective antibody titers at day 56 in >99% of subjects who received the age-appropriate dose.

Cited by 19 publications

References 22 publications

Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea

Retention of neutralizing antibodies to Japanese encephalitis vaccine in age groups above fifteen years in Korea

Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine

Reiseimpfungen bei Kindern und Jugendlichen

Contact Info

Product

Resources

About